Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
metabolite |
| gptkbp:CASNumber |
92264-81-8
|
| gptkbp:contributedTo |
therapeutic effects of bupropion
|
| gptkbp:drugClass |
norepinephrine reuptake inhibitor
nicotinic acetylcholine receptor antagonist |
| gptkbp:formedBy |
gptkb:CYP2B6
|
| gptkbp:foundIn |
human plasma
|
| gptkbp:halfLife |
20 hours
|
| gptkbp:hasMolecularFormula |
C13H18ClNO2
|
| gptkbp:hasSMILES |
CC(C)(C)NCC(C1=CC(=CC=C1)Cl)O
|
| https://www.w3.org/2000/01/rdf-schema#label |
hydroxybupropion
|
| gptkbp:isActiveMetaboliteOf |
gptkb:bupropion
|
| gptkbp:isMoreAbundantThan |
bupropion (in plasma)
|
| gptkbp:IUPACName |
(±)-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-ol
|
| gptkbp:metabolism |
gptkb:bupropion
|
| gptkbp:PubChem_CID |
CHEBI:134722
CHEMBL2103832 119543 |
| gptkbp:bfsParent |
gptkb:Bupropion
|
| gptkbp:bfsLayer |
7
|